;PMID: 1606053
;source_file_955.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..51] = [t:0..51]
;1)sentence:[e:57..172] = [t:57..172]
;2)section:[e:176..220] = [t:176..220]
;3)section:[e:224..323] = [t:224..323]
;4)sentence:[e:327..543] = [t:327..543]
;5)sentence:[e:544..744] = [t:544..744]
;6)sentence:[e:745..885] = [t:745..885]
;7)sentence:[e:886..1073] = [t:886..1073]
;8)sentence:[e:1074..1232] = [t:1074..1232]
;9)sentence:[e:1233..1364] = [t:1233..1364]
;10)section:[e:1368..1412] = [t:1368..1412]

;section 0 Span:0..51
;J Steroid Biochem Mol Biol. 1992 May;42(3-4):421-4.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..9] Steroid) (NNP:[10..17] Biochem)
        (NNP:[18..21] Mol) (NNP:[22..26] Biol) (IN:[26..27] .)
        (CD:[28..32] 1992) (NNP:[33..36] May) (CD:[36..41] ;42-LRB-3)
        (HYPH:[41..42] -) (JJ:[42..44] 4-RRB-) (CD:[44..48] :421)
        (HYPH:[48..49] -) (CD:[49..51] 4.)))

;sentence 1 Span:57..172
;Destruction of testicular cytochrome P-450 by 7 alpha-thiospironolactone is 
;catalyzed by the 17 alpha-hydroxylase.
;[83..99]:cyp450:"cytochrome P-450"
;[103..129]:substance:"7 alpha-thiospironolactone"
;[151..171]:cyp450:"17 alpha-hydroxylase"
(SENT
  (S-HLN
    (NP-SBJ-1
      (NP (NN:[57..68] Destruction))
      (PP (IN:[69..71] of)
        (NP (JJ:[72..82] testicular)
           (NN:[83..93] cytochrome) (NN:[94..99] P-450)))
      (PP (IN:[100..102] by)
        (NP (CD:[103..104] 7) (NN:[105..129] alpha-thiospironolactone))))
    (VP (VBZ:[130..132] is)
      (VP (VBN:[134..143] catalyzed)
        (NP-1 (-NONE-:[143..143] *))
        (PP (IN:[144..146] by)
          (NP-LGS (DT:[147..150] the)
             (CD:[151..153] 17) (NN:[154..171] alpha-hydroxylase)))))
    (.:[171..172] .)))

;section 2 Span:176..220
;Kossor DC, Kominami S, Takemori S, Colby HD.
(SEC
  (FRAG (NNP:[176..182] Kossor) (NNP:[183..185] DC) (,:[185..186] ,)
        (NNP:[187..195] Kominami) (NNP:[196..198] S,) (NNP:[199..207] Takemori)
        (NNP:[208..210] S,) (NNP:[211..216] Colby) (NNP:[217..220] HD.)))

;section 3 Span:224..323
;Department of Pharmacology and Toxicology, Philadelphia College of Pharmacy
;and  Science, PA 19104.
(SEC
  (FRAG (NNP:[224..234] Department) (IN:[235..237] of)
        (NNP:[238..250] Pharmacology) (CC:[251..254] and)
        (NNP:[255..265] Toxicology) (,:[265..266] ,)
        (NNP:[267..279] Philadelphia) (NNP:[280..287] College)
        (IN:[288..290] of) (NNP:[291..299] Pharmacy) (CC:[300..303] and)
        (NNP:[305..312] Science) (,:[312..313] ,) (NNP:[314..316] PA)
        (CD:[317..322] 19104) (.:[322..323] .)))

;sentence 4 Span:327..543
;Studies were done to determine the role of the 17 alpha-hydroxylase in the 
;conversion of 7 alpha-thiospironolactone (7 alpha-thio-SL) to a reactive 
;metabolite causing the degradation of testicular cytochrome P-450.
;[374..394]:cyp450:"17 alpha-hydroxylase"
;[417..443]:substance:"7 alpha-thiospironolactone"
;[445..460]:substance:"7 alpha-thio-SL"
;[477..487]:substance:"metabolite"
;[526..542]:cyp450:"cytochrome P-450"
(SENT
  (S
    (NP-SBJ-1 (NNS:[327..334] Studies))
    (VP (VBD:[335..339] were)
      (VP (VBN:[340..344] done)
        (NP-1 (-NONE-:[344..344] *))
        (S-PRP
          (NP-SBJ (-NONE-:[344..344] *))
          (VP (TO:[345..347] to)
            (VP (VB:[348..357] determine)
              (NP
                (NP (DT:[358..361] the) (NN:[362..366] role))
                (PP (IN:[367..369] of)
                  (NP (DT:[370..373] the)
                     (CD:[374..376] 17) (NN:[377..394] alpha-hydroxylase))))
              (PP (IN:[395..397] in)
                (NP
                  (NP (DT:[398..401] the) (NN:[403..413] conversion))
                  (PP (IN:[414..416] of)
                    (NP
                      (NP (CD:[417..418] 7)
                          (NN:[419..443] alpha-thiospironolactone))
                      (NP (-LRB-:[444..445] -LRB-)
                         (CD:[445..446] 7) (NN:[447..460] alpha-thio-SL)
                        (-RRB-:[460..461] -RRB-))))
                  (PP (TO:[462..464] to)
                    (NP
                      (NP (DT:[465..466] a) (JJ:[467..475] reactive)
                          (NN:[477..487] metabolite))
                      (VP (VBG:[488..495] causing)
                        (NP
                          (NP (DT:[496..499] the) (NN:[500..511] degradation))
                          (PP (IN:[512..514] of)
                            (NP (JJ:[515..525] testicular)
                               (NN:[526..536] cytochrome) (NN:[537..542] P-450))))))))))))))
    (.:[542..543] .)))

;sentence 5 Span:544..744
;Incubation of  guinea pig testicular microsomes with 7 alpha-thio-SL plus
;NADPH resulted in an  approx. 70% decline in cytochrome P-450 content and
;even greater loss of 17  alpha-hydroxylase activity.
;[597..612]:substance:"7 alpha-thio-SL"
;[618..623]:substance:"NADPH"
;[648..651]:quantitative-value:"70%"
;[663..679]:cyp450:"cytochrome P-450"
;[713..734]:substance:"17  alpha-hydroxylase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[544..554] Incubation))
      (PP (IN:[555..557] of)
        (NP (NN:[559..565] guinea) (NN:[566..569] pig)
            (JJ:[570..580] testicular) (NNS:[581..591] microsomes)))
      (PP (IN:[592..596] with)
        (NP
          (NP (CD:[597..598] 7) (NN:[599..612] alpha-thio-SL))
          (CC:[613..617] plus)
          (NP (NN:[618..623] NADPH)))))
    (VP (VBD:[624..632] resulted)
      (PP-CLR (IN:[633..635] in)
        (NP
          (NP
            (NP (DT:[636..638] an)
              (QP (RB:[640..647] approx.) (CD:[648..650] 70))
              (NN:[650..651] %) (NN:[652..659] decline))
            (PP (IN:[660..662] in)
              (NP
                (NML (NN:[663..673] cytochrome) (NN:[674..679] P-450))
                (NN:[680..687] content))))
          (CC:[688..691] and)
          (NP
            (NP
              (ADJP (RB:[692..696] even) (JJR:[697..704] greater))
              (NN:[705..709] loss))
            (PP (IN:[710..712] of)
              (NP
                (NML (CD:[713..715] 17) (NN:[717..734] alpha-hydroxylase))
                (NN:[735..743] activity)))))))
    (.:[743..744] .)))

;sentence 6 Span:745..885
;Addition of the 17 alpha-hydroxylase inhibitor,  SU-10'603, to the incubation
;medium prevented the degradation of P-450 by 7  alpha-thio-SL.
;[761..781]:cyp450:"17 alpha-hydroxylase"
;[782..791]:substance:"inhibitor"
;[794..803]:substance:"SU-10'603"
;[859..864]:cyp450:"P-450"
;[868..884]:substance:"7  alpha-thio-SL"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[745..753] Addition))
      (PP (IN:[754..756] of)
        (NP
          (NP (DT:[757..760] the)
            (NML (CD:[761..763] 17) (NN:[764..781] alpha-hydroxylase))
            (NN:[782..791] inhibitor))
          (,:[791..792] ,)
          (NP (NN:[794..803] SU-10'603))))
      (,:[803..804] ,)
      (PP (TO:[805..807] to)
        (NP (DT:[808..811] the) (NN:[812..822] incubation)
            (NN:[823..829] medium))))
    (VP (VBD:[830..839] prevented)
      (NP
        (NP (DT:[840..843] the) (NN:[844..855] degradation))
        (PP (IN:[856..858] of)
          (NP (NN:[859..864] P-450)))
        (PP (IN:[865..867] by)
          (NP (CD:[868..869] 7) (NN:[871..884] alpha-thio-SL)))))
    (.:[884..885] .)))

;sentence 7 Span:886..1073
;Similarly, preincubation of testicular microsomes with  anti-P-45017
;alpha,lyase IgG to inhibit 17 alpha-hydroxylation, diminished the  subsequent
;loss of P-450 caused by 7 alpha-thio-SL.
;[942..970]:substance:"anti-P-45017 alpha,lyase IgG"
;[1041..1046]:cyp450:"P-450"
;[1057..1072]:substance:"7 alpha-thio-SL"
(SENT
  (S
    (ADVP (RB:[886..895] Similarly))
    (,:[895..896] ,)
    (NP-SBJ
      (NP (NN:[897..910] preincubation))
      (PP (IN:[911..913] of)
        (NP (JJ:[914..924] testicular) (NNS:[925..935] microsomes)))
      (PP (IN:[936..940] with)
        (NP
          (NML (AFX:[942..946] anti) (HYPH:[946..947] -) (NN:[947..954] P-45017))
          (NN:[955..966] alpha,lyase) (NN:[967..970] IgG)))
      (S-PRP
        (NP-SBJ (-NONE-:[970..970] *))
        (VP (TO:[971..973] to)
          (VP (VB:[974..981] inhibit)
            (NP (CD:[982..984] 17) (NN:[985..1004] alpha-hydroxylation))))))
    (,:[1004..1005] ,)
    (VP (VBD:[1006..1016] diminished)
      (NP
        (NP
          (NP (DT:[1017..1020] the) (JJ:[1022..1032] subsequent)
              (NN:[1033..1037] loss))
          (PP (IN:[1038..1040] of)
            (NP (NN:[1041..1046] P-450))))
        (VP (VBN:[1047..1053] caused)
          (PP (IN:[1054..1056] by)
            (NP-LGS (CD:[1057..1058] 7) (NN:[1059..1072] alpha-thio-SL))))))
    (.:[1072..1073] .)))

;sentence 8 Span:1074..1232
;The results indicate that  the 17 alpha-hydroxylase catalyzes the conversion
;of 7 alpha-thio-SL to the  reactive metabolite responsible for P-450
;destruction.
;[1105..1125]:cyp450:"17 alpha-hydroxylase"
;[1154..1169]:substance:"7 alpha-thio-SL"
;[1187..1197]:substance:"metabolite"
;[1214..1219]:cyp450:"P-450"
(SENT
  (S
    (NP-SBJ (DT:[1074..1077] The) (NNS:[1078..1085] results))
    (VP (VBP:[1086..1094] indicate)
      (SBAR (IN:[1095..1099] that)
        (S
          (NP-SBJ (DT:[1101..1104] the)
             (CD:[1105..1107] 17) (NN:[1108..1125] alpha-hydroxylase))
          (VP (VBZ:[1126..1135] catalyzes)
            (NP
              (NP (DT:[1136..1139] the) (NN:[1140..1150] conversion))
              (PP (IN:[1151..1153] of)
                (NP (CD:[1154..1155] 7) (NN:[1156..1169] alpha-thio-SL)))
              (PP (TO:[1170..1172] to)
                (NP
                  (NP (DT:[1173..1176] the) (JJ:[1178..1186] reactive)
                      (NN:[1187..1197] metabolite))
                  (ADJP (JJ:[1198..1209] responsible)
                    (PP (IN:[1210..1213] for)
                      (NP (NN:[1214..1219] P-450) (NN:[1220..1231] destruction)))))))))))
    (.:[1231..1232] .)))

;sentence 9 Span:1233..1364
;The accompanying loss of  17 alpha-hydroxylase activity supports the
;hypothesis that suicide inhibition is  the mechanism involved.
;[1259..1279]:cyp450:"17 alpha-hydroxylase"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1233..1236] The) (VBG:[1237..1249] accompanying)
          (NN:[1250..1254] loss))
      (PP (IN:[1255..1257] of)
        (NP
          (NML (CD:[1259..1261] 17) (NN:[1262..1279] alpha-hydroxylase))
          (NN:[1280..1288] activity))))
    (VP (VBZ:[1289..1297] supports)
      (NP (DT:[1298..1301] the) (NN:[1302..1312] hypothesis)
        (SBAR (IN:[1313..1317] that)
          (S
            (NP-SBJ (NN:[1318..1325] suicide) (NN:[1326..1336] inhibition))
            (VP (VBZ:[1337..1339] is)
              (NP-PRD (DT:[1341..1344] the) (NN:[1345..1354] mechanism)
                      (VBN:[1355..1363] involved)))))))
    (.:[1363..1364] .)))

;section 10 Span:1368..1412
;PMID: 1606053 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1368..1372] PMID) (::[1372..1373] :) (CD:[1374..1381] 1606053)
        (IN:[1382..1383] -LSB-) (NNP:[1383..1389] PubMed) (HYPH:[1390..1391] -)
        (JJ:[1392..1399] indexed) (IN:[1400..1403] for)
        (NNP:[1404..1412] MEDLINE-RSB-)))
